KeyBanc Reconfirms a Hold Rating on Brandywine Realty (BDN); Selecta Biosciences (SELB) Shorts Increased By 4.27%

September 24, 2017 - By Richard Conner

Among 12 analysts covering Brandywine Realty Trust (NYSE:BDN), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. Brandywine Realty Trust has $19 highest and $13 lowest target. $16.06’s average target is -7.06% below currents $17.28 stock price. Brandywine Realty Trust had 24 analyst reports since August 14, 2015 according to SRatingsIntel. The rating was downgraded by Evercore to “In-Line” on Monday, May 15. The rating was upgraded by Evercore on Monday, December 19 to “Buy”. The rating was downgraded by JP Morgan to “Neutral” on Friday, December 16. Argus Research downgraded Brandywine Realty Trust (NYSE:BDN) on Friday, November 6 to “Hold” rating. The firm has “Sell” rating by Zacks given on Friday, August 14. The firm has “Buy” rating given on Wednesday, September 16 by S&P Research. The firm has “Buy” rating by Stifel Nicolaus given on Monday, July 17. The stock has “Equalweight” rating by Barclays Capital on Tuesday, July 19. On Friday, July 22 the stock rating was downgraded by Mizuho to “Neutral”. As per Monday, January 9, the company rating was upgraded by Raymond James.

Selecta Biosciences Incorporated (NASDAQ:SELB) had an increase of 4.27% in short interest. SELB’s SI was 938,100 shares in September as released by FINRA. Its up 4.27% from 899,700 shares previously. With 68,400 avg volume, 14 days are for Selecta Biosciences Incorporated (NASDAQ:SELB)’s short sellers to cover SELB’s short positions. The stock decreased 2.89% or $0.57 on September 22, reaching $19.17. About 255,405 shares traded or 132.95% up from the average. Selecta Biosciences Inc (NASDAQ:SELB) has 0.00% since September 24, 2016 and is . It has underperformed by 16.70% the S&P500.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $423.17 million. The Firm using its synthetic vaccine particle technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It currently has negative earnings. The Firm is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Analysts await Brandywine Realty Trust (NYSE:BDN) to report earnings on October, 18 after the close. They expect $0.35 earnings per share, up 6.06% or $0.02 from last year’s $0.33 per share. BDN’s profit will be $61.37M for 12.34 P/E if the $0.35 EPS becomes a reality. After $0.34 actual earnings per share reported by Brandywine Realty Trust for the previous quarter, Wall Street now forecasts 2.94% EPS growth.

Brandywine Realty Trust is a self-administered and self-managed real estate investment trust . The company has market cap of $3.03 billion. The Firm operates through five divisions: Pennsylvania Suburbs, Philadelphia Central Business District (CBD), Metropolitan Washington, D.C., Austin, Texas, and Other. It has a 199.91 P/E ratio. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs.

Since May 10, 2017, it had 0 insider purchases, and 1 insider sale for $153,559 activity. Shares for $153,559 were sold by DEVUONO H JEFFREY on Wednesday, May 10.